Amgen Inc.
AMGN
Clasificación en acciones
#73
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Precio por acción
$432.40
Última sincronización: 2026-10-16
Capitalización bursátil
$233.77B
Cambio (1 día)
-0.38%
Cambio (1 año)
44.71%
País
US
Comercio Amgen Inc. (AMGN)
Categoría
Healthcare
Margen Operativo de Amgen Inc. (AMGN)
Margen Operativo al October 2026 TTM: 33.18%
Según los informes financieros más recientes y el precio de las acciones de Amgen Inc., el margen operativo actual (TTM) es 33.18%. Al final de 2024, el margen operativo era 21.71%.
Historial de Margen Operativo de Amgen Inc. desde 2000 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 33.18% | -18.11% |
| 2025 | 40.52% | 86.64% |
| 2024 | 21.71% | -22.49% |
| 2023 | 28.01% | -22.92% |
| 2022 | 36.34% | 23.61% |
| 2021 | 29.40% | -18.22% |
| 2020 | 35.95% | -13.19% |
| 2019 | 41.41% | -4.19% |
| 2018 | 43.22% | -0.99% |
| 2017 | 43.65% | 2.46% |
| 2016 | 42.60% | 8.95% |
| 2015 | 39.10% | 26.70% |
| 2014 | 30.86% | -1.75% |
| 2013 | 31.41% | -2.76% |
| 2012 | 32.30% | 16.73% |
| 2011 | 27.67% | -24.89% |
| 2010 | 36.84% | -2.02% |
| 2009 | 37.60% | 8.20% |
| 2008 | 34.75% | 28.99% |
| 2007 | 26.94% | 0.11% |
| 2006 | 26.91% | -31.00% |
| 2005 | 39.00% | 22.91% |
| 2004 | 31.73% | -14.22% |
| 2003 | 36.99% | -360.31% |
| 2002 | -14.21% | -137.27% |
| 2001 | 38.13% | -3.88% |
| 2000 | 39.67% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 49.72% | -98.50% |
US
|
|
| 25.70% | -99.23% |
US
|
|
| 29.32% | -99.12% |
US
|
|
| 16.65% | -99.50% |
US
|
|
| 26.59% | -99.20% |
CH
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.